Karuna Therapeutics’ stock hits record territory after Bristol Myers’ $14 billion buyout deal

Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought by Bristol Myers Squibb.

Previous post Nike, Foot Locker shares sink after sneaker maker cuts revenue outlook
Next post Treasury yields slightly lower after subdued U.S. inflation reading in holiday-shortened session